Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma

Immunobiology

Volumn 219, Issue 6, 2014, Pages 469-474

  Singh, P K ^a   Srivastava, Anupam K ^a   Dalela, D ^a   Rath, S K ^b   Goel, M M ^a   Bhatt, M L B ^c  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c Genotoxicity Laboratory Division of Toxicology Central Drug Research Institute ^*  (India)

Author keywords

BCG; Cancer testis antigen; Immunotherapy; PBK TOPK; TCC; Vaccine

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PDZ BINDING KINASE; T LAK CELL ORIGINATED PROTEIN KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PDZ-BINDING KINASE; TUMOR MARKER;

ADULT; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS; TRANSITIONAL CELL CARCINOMA; BIOSYNTHESIS; BLADDER TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RNA, MESSENGER; TESTIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84899483849     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.02.003     Document Type: Article

References (38)

1. Abe Y., Matsumoto S., Kito K., Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J. Biol. Chem. 2000, 275:21525.
2. Abe Y., Takeuchi T., Kagawa-Miki L., Ueda N., Shigemoto K., Yasukawa M., Kito K. A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J. Mol. Biol. 2007, 370:231.
3. Ademuyiwa F.O., Bshara W., Attwood K., Morrison C., Edge S.B., Karpf A.R., James S.A., Ambrosone C.B., O'Connor T.L., Levine E.G., Miliotto A., Ritter E., Ritter G., Gnjatic S., Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 2012, 7:e38783.
4. Avritscher E.B., Cooksley C.D., Grossman H.B., Sabichi A.L., Hamblin L., Dinney C.P., Elting L.S. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006, 68:549.
5. Ayllon V., O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene 2007, 26:3451.
6. Chen Y.T., Ross D.S., Chiu R., Zhou X.K., Chen Y.Y., Lee P., Hoda S.A., Simpson A.J., Old L.J., Caballero O., Neville A.M. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS ONE 2011, 6:e17876.
7. Chen Y.T., Chiu R., Lee P., Beneck D., Jin B., Old L.J. Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum. Reprod. 2011, 26:3232.
8. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004, IARC Press, Lyon.
9. Fradet Y., Picard V., Bergeron A., LaRue H. Cancer-testis antigen expression in bladder cancer. Prog. Urol. 2006, 16:421.
10. Freitas M., Malheiros S., Stavale J.N., Biassi T.P., Zamuner F.T., de Souza Begnami M., Soares F.A., Vettore A.L. Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget 2013, 4:636.
11. Gaudet S., Branton D., Lue R.A. Characterization of PDZ-binding kinase, a mitotic kinase. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5167.
12. Goodison S., Rosser C.J., Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol. Diagn. Ther. 2013, 17:71.
13. Greene F.L., Page D.L., Fleming I.D., Fritz A.G., Balch C.M., Haller D.G., Morrow M. AJCC Cancer Staging Manual 2002, Springer, New York. 6th edn.
14. He F., Yan Q., Fan L., Liu Y., Cui J., Wang J., Wang L., Wang Y., Wang Z., Guo Y., Huang G. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma. Hum. Pathol. 2010, 41:415.
15. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277.
16. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239.
17. Kim R., Kulkarni P., Hannenhalli S. Derepression of cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation. BMC Cancer 2013, 13:144.
18. Kurashige T., Noguchi Y., Saika T., Ono T., Nagata Y., Jungbluth A., Ritter G., Chen Y.T., Stockert E., Tsushima T., Kumon H., Old L.J., Nakayama E. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001, 61:4671.
19. Lei B., Liu S., Qi W., Zhao Y., Li Y., Lin N., Xu X., Zhi C., Mei J., Yan Z., Wan L., Shen H. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression. Histopathology 2013, 63:696.
20. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402.
21. Nandi A., Tidwell M., Karp J., Rapoport A.P. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells. Mol. Dis. 2004, 32:240.
22. Nishiyama T., Tachibana M., Horiguchi Y., Nakamura K., Ikeda Y., Takesako K., Murai M. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin. Cancer Res. 2001, 7:23.
23. Obara W., Ohsawa R., Kanehira M., Takata R., Tsunoda T., Yoshida K., Takeda K., Katagiri T., Nakamura Y., Fujioka T. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer. Jpn. J. Clin. Oncol. 2012, 42:591.
24. Park J.H., Lin M.L., Nishidate T., Nakamura Y., Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006, 66:9186.
25. Patard J.J., Brasseur F., Gil-Diez S., Radvanyi F., Marchand M., Francois P., Abi-Aad A., Van Cangh P., Abbou C.C., Chopin D., et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int. J. Cancer 1995, 64:60.
26. Picard V., Bergeron A., Larue H., Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int. J. Cancer 2007, 120:2170.
27. Saini S., Jagadish N., Gupta A., Bhatnagar A., Suri A. A novel cancer testis antigen A-kinase anchor protein 4 (AKAP4) is a potential biomarker for breast cancer. PLoS ONE 2013, 8:e57095.
28. Sharma P., Gnjatic S., Jungbluth A.A., Williamson B., Herr H., Stockert E., Dalbagni G., Donat S.M., Reuter V.E., Santiago D., Chen Y.T., Bajorin D.F., Old L.J. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003, 3:19.
29. Sharma P., Shen Y., Wen S., Bajorin D.F., Reuter V.E., Old L.J., Jungbluth A.A. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin. Cancer Res. 2006, 12:5442.
30. Shih M.C., Chen J.Y., Wu Y.C., Jan Y.H., Yang B.M., Lu P.J., Cheng H.C., Huang M.S., Yang C.J., Hsiao M., Lai J.M. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 2012, 31:2389.
31. Shiraishi T., Getzenberg R.H., Kulkarni P. Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer. Asian J. Androl. 2012, 14:400.
32. Simons-Evelyn M., Bailey-Dell K., Toretsky J.A., Ross D.D., Fenton R., Kalvakolanu D., Rapoport A.P. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells. Mol. Dis. 2001, 27:825.
33. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., Newling D.W., Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006, 49:466.
34. Wei D.C., Yeh Y.C., Hung J.J., Chou T.Y., Wu Y.C., Lu P.J., Cheng H.C., Hsu Y.L., Kuo Y.L., Chen K.Y., Lai J.M. Overexpression of T-LAK cell-originated protein kinase predicts poor prognosis in patients with stage I lung adenocarcinoma. Cancer Sci. 2012, 103:731.
35. Witjes J.A., Kolli P.S. Apaziquone for non-muscle invasive bladder cancer: a critical review. Expert Opin. Investig. Drugs 2008, 17:1085.
36. Zhu F., Zykova T.A., Kang B.S., Wang Z., Ebeling M.C., Abe Y., Ma W.Y., Bode A.M., Dong Z. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology 2007, 133:219.
37. Zlobec I., Molinari F., Kovac M., Bihl M.P., Altermatt H.J., Diebold J., Frick H., Germer M., Horcic M., Montani M., Singer G., Yurtsever H., Zettl A., Terracciano L., Mazzucchelli L., Saletti P., Frattini M., Heinimann K., Lugli A. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. Br. J. Cancer 2010, 102:151.
38. Zykova T.A., Zhu F., Lu C., Higgins L., Tatsumi Y., Abe Y., Bode A.M., Dong Z. Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells. Clin. Cancer Res. 2006, 12:6884.